Development and Preliminary Clinical Evaluation of a Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain Management in Paediatric Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Postoperative Pain Intensity
研究概览
简要总结
**Brief Summary**
This study aimed to develop and conduct a preliminary clinical evaluation of a novel weight-adjusted gelatin-based diclofenac potassium medicated lollipop for the management of postoperative pain following adenotonsillectomy in children. The formulation was designed to improve analgesic adherence by providing a palatable and child-friendly dosage form suitable for oral transmucosal administration. Fifty paediatric patients aged 4 to 12 years undergoing elective adenotonsillectomy received one of three weight-adjusted diclofenac potassium lollipop doses (15 mg, 20 mg, or 30 mg) every 8 hours during the first 24 postoperative hours. The study assessed postoperative pain intensity, product acceptability, rescue analgesic use, and safety. In parallel, the formulation underwent pharmaceutical characterization, including physicochemical and microbiological quality evaluation.
详细描述
This prospective single-arm pilot study evaluated a newly developed gelatin-based diclofenac potassium medicated lollipop intended for postoperative pain management after paediatric adenotonsillectomy. The pharmaceutical formulation was optimized through iterative development and characterized by physicochemical testing, content uniformity analysis, and microbiological quality assessment according to pharmacopeial standards.
Children aged 4 to 12 years undergoing elective adenotonsillectomy received weight-adjusted diclofenac potassium lollipops (15 mg, 20 mg, or 30 mg) administered every 8 hours during the first 24 postoperative hours. Pain intensity was assessed before and after each dose using age-appropriate validated pain scales. Secondary evaluations included product acceptability, requirement for rescue analgesia, and occurrence of adverse events.
The study was designed as an exploratory pilot investigation to assess the feasibility, pharmaceutical performance, preliminary clinical effectiveness, and safety of this novel paediatric drug-delivery platform, providing the basis for future randomized controlled trials and pharmacokinetic evaluation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 4 Years 至 12 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Children aged 4 to 12 years.
- •Scheduled for elective adenotonsillectomy under general anaesthesia.
- •American Society of Anesthesiologists (ASA) physical status I or II.
- •Ability to tolerate oral administration of the medicated lollipop after surgery.
- •Written informed consent obtained from a parent or legal guardian.
排除标准
- •Known hypersensitivity or contraindication to diclofenac or other non-steroidal anti-inflammatory drugs.
- •History of asthma precipitated by NSAIDs.
- •Active gastrointestinal ulcer disease or gastrointestinal bleeding.
- •Significant hepatic, renal, cardiovascular, or coagulation disorders.
- •Severe developmental delay or neurological conditions preventing reliable pain assessment.
- •Requirement for postoperative intensive care admission.
- •Refusal of participation by the patient or parent/legal guardian.
研究组 & 干预措施
Diclofenac Potassium Medicated Lollipop
Participants received a weight-adjusted diclofenac potassium medicated lollipop (15 mg, 20 mg, or 30 mg according to body weight) every 8 hours during the first 24 postoperative hours following adenotonsillectomy for postoperative pain management.
干预措施: Diclofenac Potassium Medicated Lollipop (Drug)
结局指标
主要结局
Postoperative Pain Intensity
时间窗: 24 hours post operative
Postoperative pain intensity assessed using a 10-point Visual Analogue Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater postoperative pain intensity following administration of weight-adjusted diclofenac potassium medicated lollipops
次要结局
未报告次要终点
研究者
Joseph Alejandro Veraza Almeida
Principal Investigator
Hospital Universitario de Caracas